PSP 009
Alternative Names: PSP-009Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Prosit Sole Biotechnology
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Osteoarthritis
Most Recent Events
- 16 Oct 2024 PSP 009 is available for licensing as of 16 Oct 2024. http://www.prositsole.com/index.php?catid=38
- 16 Oct 2024 Early research in Osteoarthritis in China (unspecified route), prior to October 2024 (Prosit Sole Biotechnology pipeline, October 2024)